logo

Mesoblast Limited (MESO)



Trade MESO now with
  Date
  Headline
6/21/2018 6:02:05 AM Mesoblast Announces Key Day 100 Survival Outcomes Of Phase 3 Trial For Remestemcel-L
6/19/2018 6:05:00 AM Joseph Swedish Joins Mesoblast Board Of Directors
5/29/2018 6:09:34 AM Mesoblast Partners With Cartherics To Develop Allogeneic ‘off-the-shelf’ Cell-based Immunotherapies For Solid Cancers
5/8/2018 6:17:21 AM Mesoblast Presents Phase 3 Trial Results For Acute Graft Versus Host Disease At 2018 ISCT Annual Meeting
4/18/2018 6:03:58 AM Mesoblast Provides Update On Phase 3 And Phase 2b Clinical Trials Of MPC Product Candidate MPC-150-IM
3/28/2018 8:46:02 PM Mesoblast Phase 3 Trial For Chronic Low Back Pain Completes Enrollment
3/6/2018 7:45:15 PM Mesoblast Enters Into US$75 Million Non-Dilutive Credit Facility
2/21/2018 6:09:20 PM Mesoblast: Phase 3 Trial Of Allogeneic Mesenchymal Stem Cell Product Candidate MSC-100-IV Met Primary Endpoint